10-K Filing

BEONE MEDICINES LTD. CIK: 1651308 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001651308-22-000032`
Period End Date	20211231
Filing Date	20220228
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	bgne-20211231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 91 Income Statement 66 Cash Flow Statement 140 Stockholders Equity 33 Comprehensive Income 21

Balance Sheet 91 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.38B	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.38B	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$307.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$328.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.33B	shares	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.19B	shares	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$2.24B	USD	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.33B	shares	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.19B	shares	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$3.27B	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$483.11M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$60.40M	USD	Point-in-time
Inventories	`InventoryNet`	$89.29M	USD	Point-in-time
Inventories	`InventoryNet`	$242.63M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$160.01M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$270.17M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.96B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$7.61B	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$6.88M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$7.75M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$587.61M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$357.69M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$90.58M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$117.43M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$46.68M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.00M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$65.96M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$110.42M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$163.05M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$113.09M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$640.07M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$1.03B	USD	Point-in-time
Total assets	`Assets`	$8.65B	USD	Point-in-time
Total assets	`Assets`	$5.60B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$231.96M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$262.40M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$346.14M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$558.05M	USD	Point-in-time
Deferred revenue, current portion	`ContractWithCustomerLiabilityCurrent`	$187.41M	USD	Point-in-time
Deferred revenue, current portion	`ContractWithCustomerLiabilityCurrent`	-	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$20.38M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$21.39M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$21.93M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$13.89M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$120.80M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$127.81M	USD	Point-in-time
Short-term debt	`LongTermDebtCurrent`	$335.01M	USD	Point-in-time
Short-term debt	`LongTermDebtCurrent`	2.72B	CNY	Point-in-time
Short-term debt	`LongTermDebtCurrent`	2.19B	CNY	Point-in-time
Short-term debt	`LongTermDebtCurrent`	$427.56M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.08B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.60B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$202.11M	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	1.29B	CNY	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$183.64M	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	1.20B	CNY	Point-in-time
Deferred revenue, non-current portion	`ContractWithCustomerLiabilityNoncurrent`	$220.29M	USD	Point-in-time
Deferred revenue, non-current portion	`ContractWithCustomerLiabilityNoncurrent`	-	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$29.42M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$43.04M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$10.79M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$14.17M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$375.04M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$269.56M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$57.43M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$54.23M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$656.32M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$803.41M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.73B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.40B	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,334,804,281 and 1,190,821,941 shares issued and outstanding as of December 31, 2021 and 2020, respectively	`CommonStockValue`	$133.00K	USD	Point-in-time
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,334,804,281 and 1,190,821,941 shares issued and outstanding as of December 31, 2021 and 2020, respectively	`CommonStockValue`	$118.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$7.41B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$11.19B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$6.94M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$17.95M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.55B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.97B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$6.24B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$3.87B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$5.60B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$8.65B	USD	Point-in-time

Income Statement 66 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$1.18B	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$308.87M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$428.21M	USD	Annual
Cost of sales - product	`CostOfGoodsAndServicesSold`	$70.66M	USD	Annual
Cost of sales - product	`CostOfGoodsAndServicesSold`	$164.91M	USD	Annual
Cost of sales - product	`CostOfGoodsAndServicesSold`	$71.19M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.46B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.29B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$927.34M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$600.18M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$388.25M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$990.12M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$1.72M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$846.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$1.33M	USD	Annual
Total expenses	`CostsAndExpenses`	$1.39B	USD	Annual
Total expenses	`CostsAndExpenses`	$1.97B	USD	Annual
Total expenses	`CostsAndExpenses`	$2.62B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-959.89M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-1.44B	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-1.66B	USD	Annual
Interest (expense) income, net	`InterestIncomeExpenseNet`	$2.00M	USD	Annual
Interest (expense) income, net	`InterestIncomeExpenseNet`	$9.13M	USD	Annual
Interest (expense) income, net	`InterestIncomeExpenseNet`	$-15.76M	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$15.90M	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$37.49M	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$7.17M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-943.59M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.62B	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.44B	USD	Annual
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$6.99M	USD	Annual
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-25.23M	USD	Annual
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-17.67M	USD	Annual
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-1.41B	USD	Annual
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.95M	USD	Annual
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-3.62M	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-1.41B	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-1.60B	USD	Annual
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-948.63M	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	`EarningsPerShareBasic`	$-1.22	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	`EarningsPerShareBasic`	$-1.17	USD	Annual
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	`EarningsPerShareBasic`	$-1.47	USD	Annual
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.22	USD	Annual
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.17	USD	Annual
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.47	USD	Annual
Weighted average shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	780.70M	shares	Annual
Weighted average shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.21B	shares	Annual
Weighted average shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	Annual
Weighted average shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.21B	shares	Annual
Weighted average shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	780.70M	shares	Annual
Weighted average shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	Annual
Net loss per American Depositary Share (ADS), basic (in dollars per share)	`EarningsPerAmericanDepositoryShareBasic`	$-15.80	USD	Annual
Net loss per American Depositary Share (ADS), basic (in dollars per share)	`EarningsPerAmericanDepositoryShareBasic`	$-15.23	USD	Annual
Net loss per American Depositary Share (ADS), basic (in dollars per share)	`EarningsPerAmericanDepositoryShareBasic`	$-19.13	USD	Annual
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	`EarningsPerAmericanDepositoryShareDiluted`	$-15.80	USD	Annual
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	`EarningsPerAmericanDepositoryShareDiluted`	$-19.13	USD	Annual
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	`EarningsPerAmericanDepositoryShareDiluted`	$-15.23	USD	Annual
Weighted-average ADSs outstanding, basic (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic`	60.05M	shares	Annual
Weighted-average ADSs outstanding, basic (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic`	83.47M	shares	Annual
Weighted-average ADSs outstanding, basic (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic`	92.79M	shares	Annual
Weighted-average ADSs outstanding, diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted`	92.79M	shares	Annual
Weighted-average ADSs outstanding, diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted`	60.05M	shares	Annual
Weighted-average ADSs outstanding, diluted (in shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted`	83.47M	shares	Annual

Cash Flow Statement 140 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-1.41B	USD	Annual
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$46.46M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$31.79M	USD	Annual
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$18.62M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$134.15M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$183.48M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$240.71M	USD	Annual
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	$83.50M	USD	Annual
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	$69.00M	USD	Annual
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	$109.50M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	$-112.49M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	$-113.99M	USD	Annual
Amortization of research and development cost share liability	`AmortizationOfResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Income (Loss) from Equity Method Investments	`IncomeLossFromEquityMethodInvestments`	-	USD	Annual
Income (Loss) from Equity Method Investments	`IncomeLossFromEquityMethodInvestments`	$7.63M	USD	Annual
Income (Loss) from Equity Method Investments	`IncomeLossFromEquityMethodInvestments`	$11.83M	USD	Annual
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-9.23M	USD	Annual
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-27.81M	USD	Annual
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-41.09M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-4.67M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$23.51M	USD	Annual
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-1.40M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-10.36M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$29.82M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$423.02M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$58.91M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$153.33M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$12.31M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$107.13M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$56.22M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$20.74M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.22M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$20.01M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$95.83M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$140.04M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$71.60M	USD	Annual
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$185.01M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-27.98M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	-	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$407.70M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$-2.62M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$6.20M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$-25.50M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-750.27M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.30B	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.28B	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$117.51M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$89.61M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$262.94M	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$1.17B	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$2.15B	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$5.66B	USD	Annual
Proceeds from sale or maturity of short-term investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$2.75B	USD	Annual
Proceeds from sale or maturity of short-term investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$3.15B	USD	Annual
Proceeds from sale or maturity of short-term investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$1.88B	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$8.50M	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$109.50M	USD	Annual
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$69.00M	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$43.41M	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of long-term investments	`PaymentsToAcquireLongtermInvestments`	-	USD	Annual
Purchase of long-term investments	`PaymentsToAcquireLongtermInvestments`	$43.50M	USD	Annual
Purchase of long-term investments	`PaymentsToAcquireLongtermInvestments`	$26.68M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$2.02M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$554.16M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$640.66M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.17B	USD	Annual
Proceeds from public offering, net of cost	`ProceedsFromIssuanceInitialPublicOffering`	$3.39B	USD	Annual
Proceeds from public offering, net of cost	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	Annual
Proceeds from public offering, net of cost	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	$50.00M	USD	Annual
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStock`	$4.23B	USD	Annual
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	$616.83M	USD	Annual
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	-	USD	Annual
Payment to acquire joint venture (JV) minority interest	`PaymentsToAcquireInterestInJointVentureFinancingActivities`	-	USD	Annual
Payment to acquire joint venture (JV) minority interest	`PaymentsToAcquireInterestInJointVentureFinancingActivities`	$28.72M	USD	Annual
Payment to acquire joint venture (JV) minority interest	`PaymentsToAcquireInterestInJointVentureFinancingActivities`	-	USD	Annual
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$67.49M	USD	Annual
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$110.21M	USD	Annual
Proceeds from long-term loan	`ProceedsFromLongTermLinesOfCredit`	$16.84M	USD	Annual
Repayment of long-term loan	`RepaymentsOfLongTermDebt`	$132.06M	USD	Annual
Repayment of long-term loan	`RepaymentsOfLongTermDebt`	-	USD	Annual
Repayment of long-term loan	`RepaymentsOfLongTermDebt`	$32.81M	USD	Annual
Proceeds from short-term loans	`ProceedsFromShortTermDebt`	$323.70M	USD	Annual
Proceeds from short-term loans	`ProceedsFromShortTermDebt`	-	USD	Annual
Proceeds from short-term loans	`ProceedsFromShortTermDebt`	$406.45M	USD	Annual
Repayment of short-term loans	`RepaymentsOfShortTermDebt`	$12.25M	USD	Annual
Repayment of short-term loans	`RepaymentsOfShortTermDebt`	-	USD	Annual
Repayment of short-term loans	`RepaymentsOfShortTermDebt`	$321.75M	USD	Annual
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	$4.00M	USD	Annual
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	-	USD	Annual
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	-	USD	Annual
Proceeds from option exercises and employee share purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$92.76M	USD	Annual
Proceeds from option exercises and employee share purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$47.00M	USD	Annual
Proceeds from option exercises and employee share purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$93.10M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.64B	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.20B	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$85.68M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.23M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-9.51M	USD	Annual
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.04M	USD	Annual
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$2.99B	USD	Annual
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$769.23M	USD	Annual
Net increase (decrease) in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-119.94M	USD	Annual
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.39B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.38B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.39B	USD	Point-in-time
Cash, cash equivalents, and restricted cash, end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$4.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.38B	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$307.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$328.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$6.88M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$7.75M	USD	Point-in-time
Income taxes paid	`IncomeTaxesPaidNet`	$10.60M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$8.98M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$15.70M	USD	Annual
Interest paid	`InterestPaidNet`	$44.13M	USD	Annual
Interest paid	`InterestPaidNet`	$29.97M	USD	Annual
Interest paid	`InterestPaidNet`	$4.32M	USD	Annual
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$29.09M	USD	Annual
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$42.76M	USD	Annual
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$53.20M	USD	Annual
Purchase of in-process research and development included in accounts payable	`AcquiredInProcessResearchAndDevelopmentButNotYetPaid`	$75.00M	USD	Annual
Purchase of in-process research and development included in accounts payable	`AcquiredInProcessResearchAndDevelopmentButNotYetPaid`	-	USD	Annual
Purchase of in-process research and development included in accounts payable	`AcquiredInProcessResearchAndDevelopmentButNotYetPaid`	-	USD	Annual

Stockholders Equity 33 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.87B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$6.24B	USD	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.33B	shares	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.19B	shares	Point-in-time
Contributions from shareholders	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$4.00M	USD	Annual
Issuance of ordinary shares in connection	`StockIssuedDuringPeriodValueNewIssues`	$2.07B	USD	Annual
Issuance of ordinary shares in connection	`StockIssuedDuringPeriodValueNewIssues`	$50.00M	USD	Annual
Exercise of options, ESPP and release of RSUs	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$93.10M	USD	Annual
Exercise of options, ESPP and release of RSUs	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$92.76M	USD	Annual
Exercise of options, ESPP and release of RSUs	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$47.00M	USD	Annual
Use of shares reserved for share option exercises and RSU releases	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.00K	USD	Annual
Use of shares reserved for share option exercises and RSU releases (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	17.23M	shares	Annual
Use of shares reserved for share option exercises and RSU releases (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	29.71M	shares	Annual
Use of shares reserved for share option exercises and RSU releases (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	16.73M	shares	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition`	$134.15M	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition`	$183.48M	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition`	$240.71M	USD	Annual
Deconsolidation of a subsidiary	`NoncontrollingInterestDecreaseFromDeconsolidation`	$3.54M	USD	Annual
Acquisition of joint venture (JV) minority interest	`AcquisitionOfJointVentureMinorityInterest`	$28.71M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$11.01M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$15.07M	USD	Annual
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-9.87M	USD	Annual
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-1.41B	USD	Annual
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$3.87B	USD	Point-in-time
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the ending of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$6.24B	USD	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.33B	shares	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.19B	shares	Point-in-time

Comprehensive Income 21 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-950.58M	USD	Annual
Net loss	`ProfitLoss`	$-1.41B	USD	Annual
Net loss	`ProfitLoss`	$-1.60B	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-9.42M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$23.60M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$13.71M	USD	Annual
Pension liability adjustments	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$8.11M	USD	Annual
Pension liability adjustments	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-1.86M	USD	Annual
Pension liability adjustments	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	-	USD	Annual
Unrealized holding loss, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-448.00K	USD	Annual
Unrealized holding loss, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-419.00K	USD	Annual
Unrealized holding loss, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.57M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-960.45M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-1.40B	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-1.59B	USD	Annual
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-3.49M	USD	Annual
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	-	USD	Annual
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-2.29M	USD	Annual
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-1.40B	USD	Annual
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-958.15M	USD	Annual
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-1.58B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.